The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34222
Abstract: Two Janus‐associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate‐risk and high‐risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease… read more here.
Keywords: clinical dilemma; jaki; inhibitor; myelofibrosis ... See more keywords